Long Grove Pharmaceuticals

What Long Grove Pharmaceuticals does

Long Grove Pharmaceuticals, LLC is a specialized generic injectable pharmaceutical company founded in 2022 and headquartered in Rosemont, Illinois, operating as a subsidiary of Capstone Development Services Company, LLC. The company develops and commercializes differentiated sterile injectable and ready-to-use premix medications targeting critical-care, women's health, oncology, ophthalmic diagnostics, and other hospital-administered indications, including Premix Vasopressin, Premix Norepinephrine, AK-FLUOR Fluorescein Injection, Carboprost Tromethamine, Cyclophosphamide, Eribulin Mesylate, Dalbavancin, Methadone Hydrochloride, Sodium Bicarbonate, and Triamcinolone Acetonide. Products are developed in-house using 505(b)(2) and ANDA regulatory pathways, are FDA-approved with AP or AB therapeutic-equivalence ratings, and several are TAA compliant; manufacturing is executed through partnerships with established global manufacturers primarily in Europe and North America, making the company asset-light on the production side.

The company's core technical differentiators are its proprietary 2-VIEW Labeling System — a clear, at-a-glance label design intended to reduce look-alike/sound-alike medication errors — and its positioning around supply-chain reliability and the U.S. drug-shortage narrative. Long Grove generates revenue through one-time sales of prescription generic pharmaceutical products distributed via major U.S. wholesalers (Cardinal, Cencora, McKesson, Morris & Dickson, Besse, Clint, McKesson Medical-Surgical) and direct enterprise relationships with hospitals, IDNs, and GPOs. GTM is an enterprise field-sales model with a national accounts team and five regional Major Account Executives covering the North East, Southeast, Midwest, Southwest, and West. Pricing is not publicly disclosed; products are sold by prescription through licensed healthcare professionals. Notable commercial relationships include a strategic partnership with Premier, Inc. for norepinephrine IV bag supply (announced September 2024) and a co-development relationship with Sunny Pharmtech for Cyclophosphamide (December 2023). The company is a member of the End Drug Shortages Alliance and sponsors Angels for Change, reinforcing its institutional positioning around supply-chain continuity. No revenue figures, funding rounds, or AI/ML capabilities are disclosed in the source material.

Name

Long Grove Pharmaceuticals

Legal name

Long Grove Pharmaceuticals, LLC

Website

https://longgrovepharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Long Grove Pharmaceuticals is a U.S. specialty generic pharmaceutical company that develops and distributes FDA-approved ready-to-use premix and sterile injectable medications through major wholesalers to hospitals, IDNs, and GPOs.

Ownership category

akta.pro rank

Product category

Specialty Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Generic injectables
• Sterile injectables
• Ready-to-use premix
• Specialty pharmaceutical manufacturing
• Critical care medications

Headquarters

HQ city

Rosamond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Long Grove generates revenue through the sale of generic pharmaceutical products including ready-to-use premix injectables, sterile injectables, and other generic medications. Products are sold through wholesale distribution channels to hospitals and healthcare providers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Long Grove Pharmaceuticals manufactures and distributes a portfolio of FDA-approved, differentiated generic injectable medications for U.S. critical care settings, anchored by ready-to-use premix formulations (Premix Vasopressin and Premix Norepinephrine in 0.9% Sodium Chloride) and a sterile injectable portfolio. Products are developed in-house through 505(b)(2) and ANDA pathways and sold through major pharmaceutical wholesalers and direct enterprise sales to hospitals, IDNs, and GPOs. The company differentiates through its proprietary 2-VIEW labeling system and an owned supply chain designed to mitigate U.S. drug shortages.

Product overview

Long Grove Pharmaceuticals is a specialized generic pharmaceutical company offering a portfolio of differentiated injectable medications. The company operates two main product categories: Ready-to-Use Premix solutions (Premix Vasopressin and Premix Norepinephrine in 0.9% Sodium Chloride) and a broader Sterile Injectable portfolio. The sterile injectable portfolio includes AK-FLUOR Fluorescein Injection, Carboprost Tromethamine Injection, Cyclophosphamide for Injection, Dalbavancin for Injection, Eribulin Mesylate Injection, Methadone Hydrochloride Injection, Sodium Bicarbonate Injection, and Triamcinolone Acetonide Injectable Suspension. Products are developed using 505(b)(2) and ANDA regulatory pathways and feature differentiated labeling designed to improve patient safety.

Differentiator

Problem solved

Functional benefit

Products and services

• Premix Vasopressin in 0.9% Sodium Chloride FDA-approved, ready-to-use premix vasopressin in 0.9% sodium chloride for critical care needs. Available in 20 units/100 mL and 40 units/100 mL concentrations with crystal clear 2-VIEW labeling for easy bedside identification, supplied to U.S. hospitals and healthcare systems.
• Premix Norepinephrine in 0.9% Sodium Chloride FDA-approved, ready-to-use premix norepinephrine in 0.9% sodium chloride available in three strengths (4 mg/250 mL, 8 mg/250 mL, and 16 mg/250 mL) with a 24-month shelf life at room temperature, intended for critical care use in hospitals and healthcare systems.
• AK-FLUOR Fluorescein Injection, USP 10% AK-FLUOR Fluorescein Injection for ophthalmic diagnostic use as a single-dose vial (100 mg/mL, 5 mL fill volume), AP Rated and preservative-free, supplied to hospitals and ophthalmic practices in the United States.
• Carboprost Tromethamine Injection, USP Women's health injectable at 250 mcg/mL supplied in single-dose 1 mL vials in 1-pack and 10-pack presentations, AP Rated and Made in Canada, used in hospital obstetric and postpartum hemorrhage settings.
• Cyclophosphamide for Injection, USP Chemotherapy medication available in 500 mg, 1 g, and 2 g single-dose vial presentations, AP Rated, preservative-free, and TAA Compliant, for oncology use in hospitals and infusion centers.
• Dalbavancin for Injection 500 mg single-dose vial for injection, AP Rated and preservative-free, supplied as a generic equivalent to the brand DALVANCE for use in acute bacterial skin and skin structure infections.
• Eribulin Mesylate Injection Oncology medication supplied as a 1 mg/2 mL single-dose vial, AP Rated and TAA Compliant, as a generic equivalent to the brand Halaven for hospital oncology and infusion settings.
• Methadone Hydrochloride Injection, USP 200 mg/20 mL multiple-dose vial at 10 mg/mL, AP Rated and Made in the USA, used in hospitals and healthcare facilities for pain management and opioid use disorder treatment settings.
• Sodium Bicarbonate Injection, USP 8.4% Sodium Bicarbonate Injection (50 mEq/50 mL) in single-dose vials, AP Rated and preservative-free, supplied to hospitals for critical care and emergency use.
• Triamcinolone Acetonide Injectable Suspension, USP Corticosteroid injectable available in 40 mg/mL concentration in 1 mL single-dose and 5 mL/10 mL multiple-dose vial presentations, AB Rated, TAA Compliant, and Made in the EU, as a generic equivalent to Kenalog-40 for hospitals and alternate-site providers.

Quantifiable outcome

• Ready-to-use premix helps enhance efficiency and effectiveness of pharmacy operations
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Premier, Inc.coreStrategic or Co-development Partner · 1 September 2024Premier, Inc. and Long Grove Pharmaceuticals joined forces in September 2024 to increase supply of norepinephrine IV bags. This partnership addresses critical drug shortages and ensures reliable access to essential critical care medications for healthcare facilities across the United States.
• Sunny PharmtechcoreStrategic or Co-development Partner · 1 December 2023Long Grove Pharmaceuticals partnered with Sunny Pharmtech in December 2023 to launch a chemotherapy medication, expanding their product portfolio into oncology treatments.
• End Drug Shortages Alliance (EDSA)coreOthers · 1 January 2023Long Grove Pharmaceuticals joined the End Drug Shortages Alliance in January 2023 as a proud member. The company is committed to solving pharmaceutical supply chain challenges that disrupt access to essential medications across the United States.
• Angels for ChangeminorOthersLong Grove Pharmaceuticals sponsors and supports Angels for Change, a nonprofit organization dedicated to ending drug shortages through advocacy, awareness, and a resilient supply chain.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Baxter International: Major hospital products company with injectable pharmaceuticals, IV solutions, and ready-to-use premix products. Multiple Long Grove executives (including John Wass, Jessica Reynolds, and Brian Van Dyke) have Baxter backgrounds, indicating close competitive overlap and shared commercial relationships.
• Hikma Pharmaceuticals: Larger generic pharmaceutical company with a significant US injectable portfolio competing in the same hospital injectable space. Public company (NYSE: HIK) with broader international footprint and deeper capital resources than Long Grove.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a significant injectable portfolio in the US hospital channel. Teva competes broadly across many of Long Grove's therapeutic categories with substantially greater scale and resources.
• Pfizer CentreOne (formerly Hospira Injectables): Pfizer's contract manufacturing and generic injectables arm, the largest US injectable generics competitor with long-standing supplier relationships to virtually every US hospital. Several Long Grove executives have Hospira backgrounds, reflecting the company's strong incumbent position.
• B. Braun Medical: Major medical device and pharmaceutical company with a significant IV solutions and injectable pharmaceutical portfolio serving US hospitals. Competes directly with Long Grove in IV fluids and premix presentations.

Direct peers

• Xellia Pharmaceuticals: Specialty injectable pharmaceutical company focused on anti-infectives and critical care injectables. Multiple Long Grove executives (including John Wass and Matt Henderson) have Xellia backgrounds, indicating deep competitive overlap and shared customer relationships in the US hospital channel.
• Sagent Pharmaceuticals: Specialty generic injectable company focused on hospital products with a similar product strategy of differentiated packaging and labeling. Sagent's acquisition by Nichi-Iko for approximately $700M in 2019 provides a recent valuation benchmark for a comparable specialty injectable business.
• Eagle Pharmaceuticals: Specialty injectable pharmaceutical company focused on hospital products, particularly premix formulations and oncology injectables. Eagle's strategy of 505(b)(2) regulatory pathway differentiation and ready-to-use presentations closely mirrors Long Grove's approach, making it one of the most directly comparable peers.
• Fresenius Kabi: Global leader in generic injectable pharmaceuticals and IV solutions, with a portfolio that directly overlaps Long Grove across premix formulations, oncology, and critical care injectables. Multiple Long Grove executives previously worked at Fresenius Kabi, signaling close competitive intelligence and direct head-to-head competition in the US hospital channel.
• Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company focused on injectable, intranasal, and inhalation products with a comparable product strategy including differentiated presentations and shortage-focused portfolio. Public company (NASDAQ: AMPH) provides a direct comparable for specialty injectable economics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/long-grove-pharmaceuticals

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Long Grove Pharmaceuticals